AOD 9604 5mg we yu de yuz

▎ AOD 9604 Struktrɔ

Sos: PubChem

Sikyɔn: SALLRSIPAPAGASRLLLLTGEIDLP Mɔlikul Fɔmula: C 78H 123N 23O 23S2 Molikul Weyt: 1815.1g/mol CAS Nɔmba: 221231-10-3 PubChem CID: 71300630, ɛn di ɔda wan dɛn

▎ AOD 9604 Risach

Wetin na di risach bakgrɔn fɔ AOD 9604?

AOD 9604 na pεptida we kכmכp fכ di C-tεrminal fragmεnt fכ di hכman gכt hכmon (hGH), spεshal wan di amino asid sikεns 177 - 191, wit adishכnal tayrosin rεsidεns na di N-tεrminus fכ di pεptida.

Di rilayshɔn bitwin AOD 9604, growth ɔmon, ɛn ɔbisiti tritmɛnt na dis. Pan ɔl we di ɔmon we de mek pɔsin gro (hGH) gɛt di pawa fɔ trit pɔsin we fat, di tin dɛn we de mek pɔsin nɔ ebul fɔ yuz am fɔ lɔng tɛm. as C-tεrminal fragmεnt fכ hGH, dεn kכnsidr AOD 9604 fכ pכtεnshal fכ ple rol fכ trit fכs we nכ de kכz di nεgεtiv ifekt dεm fכ hGH. stכdi dεn fכnshכn se כl tu hGH εn AOD 9604 kin indyuz weit lכs εn inkrεs lipolytic sεnsitiviti afta lכng tεm tritmεnt insay mays. wan poshubul mεkanism na tru intarakshכn wit di β-adrenergic path, spεshal wan wit di beta (3)-adrenergic risεptor dεm (β3-AR) ^[1]. .

כl tu di hGH εn AOD 9604 kin ridyus di bכdi wet εn di bכdi fεt fכ di fat mays dεm, εn dis rizulεt de riliyt to di inkrεs εksprεshכn lεvεl fכ β3-AR RNA, di men lipolytic rεsεpכta insay adiposyt dεm. imכtant, כl tu di hGH εn AOD 9604 kin inkrεs di suprεs β3-AR RNA lεvεl dεm na obes mays to wan lεvεl we kכmparabl wit di wan we sכm sכm mays dεm ^[1]. .

כltu, in β3-AR knockout mays, lכng tεm yus כf hGH εn AOD 9604 fεl fכ prodyuz di wet chenj dεm εn inkrεs lipolysis we dεn obsεv in wayl-tayp kכntrכl mays. bכt in akyu εkspεriεns, AOD 9604 kin inkrεs di enεji kכnsכmshכn εn fεt כksidεshכn in β3-AR kכkכt mays ^[1]..

Tritmɛnt fɔ ɔstiɔ-arayt: Intra-atikul injɛkshɔn fɔ AOD 9604 dɔn sho sɔm kɔretiv ifɛkt dɛn na wan rɔbish mɔdel fɔ ɔstiɔ-arayt. di risach we Kwon Dong Rak εn Park Gi Young du sho se ultrasound-guided intra-articular injεkshכn fכ AOD 9604 de εnhans di kכtilaj rigεnεshכn, εn di kכmbayn injεkshכn fכ AOD 9604 εn hyaluronic acid (HA) de mכr ifektiv pas fכ yuz HA כ AOD 9604 nכmכ ^[2]. .

dεn ripot se AOD 9604 de miks di lipolytic prכpati dεm fכ di growth כmon we nכ gεt di sayd ifekt fכ indyuz dayabεtis. So, dɛn kin yuz am as drɔg we de ɛp pɔsin fɔ wok fayn ɛn di Wɔl Anti-doping Ajɛns (WADA) nɔ gri fɔ du am ^[3]..

di risach bakgrכn fכ AOD 9604 mεnli kכmכt frכm di kכntradikshכn bitwin di pכtεnshal fכ hכmon gכt hכmon fכ trit fכ fat εn in sefty ishu dεm. pan di sem tεm, wit di inkrεs pan mεtabolik sik dεm, in pכtεnshal rol fכ impruv mεtabolik hεlth εn in sef dεn dכn bi di fכs fכ risεch.

Wetin na di kכntribyushכn εn advantej dεm fכ di mεkanism fכ akshכn fכ AOD 9604 insay weit lכs εn mεtabolik rεguleshכn?

fכs, insay di tεm dεm fכ lipolysis, AOD 9604 de sכmtεm εnhans di sεnsitiviti fכ lipolysis bay we i de aktibכt di β3-adrenergic rεsεpכta (β3-AR) path fכ adiposyt dεm. dis aktibכshכn de mek di adiposyt dεm ebul fכ brok dכn di triglisεrayd dεm we dεn stכr mכr ifektiv wan insay fri fεt asid dεm εn glisεrol, so dat de protεkt di dεkomposishכn εn yutilizeshכn fכ fεt fכ gi enεji fכ di bכdi. dis prכsεs nכ de כnli εp fכ ridyus di fεt we de kכmכt na di bכdi bכt i de εp fכ mek di bכdi fεt distribushכn fayn, i de ridyus di prכpכshכn fכ di vishכnal fεt, εn so i de ridyus di risk fכ difrεn sik dεm we de fכ fat, lεk kכdivaskyul sik dεm εn tayp 2 dayabitis.

sεkכn, AOD 9604 de du fayn bak fכ inhεbit lipojεnεsis. i kin mek di fεt we de kכmכt frכm di it we yu it nכ kכnvכlt to bכdi fεt bay we i de rεgεl di εksprεshכn fכ di jin dεm we riliyt to lipojεnεsis. spεshal wan, AOD 9604 kin inhεbit di aktvכti fכ di kכl lipojenik εnzym dεm lεk fεt asid sεntez, we de ridyus di sεntesis εn stכrej fכ fεt asid dεm. dis inhibitory ifekt de εp fכ ridyus di proliferashכn εn difrεns fכ di adiposyt dεm εn fכ mek di adipos tisu dεm nכ de εkspכn pasmak, so dat de mek di ifekt we de fכ lכs di wet. di sem tεm, dis inhibitory ifekt kin εp bak fכ mεnten di bεlε pan di bכdi in fεt mεtabolism εn avכyd mεtabolik dizכrd dεm we kכz fכ fεt we de kכmכt pasmak.

we i kam pan mεtabolik rεguleshכn, di rol we AOD 9604 de ple na mכr komplεks εn kכmprεhεnsiv. i kin shift di bכdi in enεji mεtabolism frכm glukכs mεtabolism to fεt mεtabolism, εn dis shift na big minin fכ lכs weit εn impruv mεtabolik hεlth. bay we i de inkrεs di oksidativ dεkomposishכn fכ di fεt asid dεm, AOD 9604 de gi mכr enεji sכs fכ di bכdi εn i de ridyus di dipεndεns pan glukכs mεtabolism. dis mεtabolik rεguleshכn nכ de כnli εp fכ inkrεs di basal mεtabolik rεt, we de mek di bכdi kכnsכm mכr εnεji we i de rεst, bכt i de impruv insulin sεnsitiviti, i de protεkt di כptek εn yutilizeshכn fכ glukכs, εn so i de mεnten di stεbiliti fכ di bכdi shuga lεvεl. apat frכm dat, dis mεtabolik rεguleshכn ifekt de εp bak fכ ridyus di dεposit fεt na כgan dεm lεk di liva, fכ prεvεnt εn impruv mεtabolik sik dεm lεk fεt liva.

Fɔ dɔn, AOD 9604 gɛt spɛshal bɛnifit dɛn fɔ ridyus insulin rɛsistɛns. We yu kɔmpia am wit di kɔmplit ɔmon we de gro, AOD 9604 de pul di sayd ɛfɛkt dɛn we kin mek pɔsin nɔ gɛt insulin ɛn i kin mek di blɔd shuga go ɔp. Dis impɔtant tin de mek AOD 9604 sef we dɛn de du di tritmɛnt ɛn i nɔ go gɛt bad impak pan di blɔd shuga lɛvɛl. Dis gɛt impɔtant klinik minin fɔ di wan dɛn we fat, mɔ di wan dɛn we gɛt insulin rɛsistɛns ɔ abnɔmal blɔd shuga. AOD 9604 nɔ kin jɔs ɛp dɛn fɔ lɔs dɛn wet bɔt i kin ɛp dɛn fɔ mek dɛn gɛt insulin sɛnsitiviti, i kin ridyus di risk fɔ gɛt tayp 2 dayabitis, ɛn i kin ɛp dɛn fɔ mek di ɔl mɛtabolik wɛlbɔdi lɛvɛl bɛtɛ.

fכ kכnklud, AOD 9604 de εksεrt in ifekt pan weit lכs εn mεtabolik rεguleshכn tru mכltipכl mεkanism dεm fכ akshכn, we de gi nyu chכys εn op fכ di tritmεnt fכ fat εn mεtabolik sik dεm.

Efεkt כf AOD9604 pan kumulativ bכdi wet gεn כf Zucker (fa/fa) rat. Dɛn bin gi di tɛst animal dɛn (p) ɛvride wan ɔral doz we na 500 Ìg AOD9604 fɔ ɛni bɔdi wet fɔ 20 dez, ɛn di kɔntrol animal dɛn (P) bin gɛt ikwal volyum fɔ salin ɛvride insay di sem we. Rizult na min B SEM fɔ 8 animal dɛn. Dɛn kin sho impɔtant difrɛns dɛn wit wan asterisk.

Sos:PubMed ^{[5] we dɛn pul am.}

Wetin na di spεsifi k link dεm we AOD 9604 de afekt fεt mεtabolism tru?

intarakshכn wit di β-adrenergic path: stכdi dεn sho se hGH εn di lipolytic fragmεnt AOD 9604 we dεn sεntez frכm in C-tεrminal kin indyuz weit lכs εn inkrεs lipolytic sεnsitiviti afta lכng tεm tritmεnt insay mays ^[4] . wan poshubul mεkanism na tru intarakshכn wit di β-adrenergic path, spεshal wan wit di β3-adrenergic rεsεpכta (β3-AR). insay obes mays, hGH εn AOD 9604 kin inkrεs di εksprεshכn lεvεl fכ β3-AR RNA εn kin inkrεs di suprεs β3-AR RNA lεvεl in obes mays to wan lεvεl we kכmparabl wit di wan we sכm sכm mays dεm. כltu, lכng tεm tritmεnt fכ β3-AR knockout mays wit hGH εn AOD 9604 fεl fכ prodyuz di wet chenj dεm εn inkrεs lipolysis we dεn obsεv in wayl-tayp kכntrכl mays. bכt in akyu εkspεriεns, AOD 9604 kin inkrεs di enεji kכnsכmshכn εn fεt כksidεshכn in β3-AR knockout mays. dis de sho se di lipolytic ifekt dεm fכ hGH εn AOD 9604 nכ de mεdiet dεn dairekt wan bay β3-AR, pan כl we dεn tu kin inkrεs di εksprεshכn fכ β3-AR, we kin εp afta dat fכ εnhans lipolytic sεnsitiviti.

inkrεs fεt כksidεshכn εn stimulate lipolysis: Insay fat (ob/ob) εn slim C57BL/6J mays dεm, dεn kin si di krכnik ifekt dεm we di hכmon gכt hכmon (hGH) εn AOD 9604 (di C-tεrminal fragmεnt fכ hGH) de gi pan bכdi wet, εnεji bεlε, εn sabstεrayt כksidεshכn rεt. כl tu di hGH εn AOD 9604 sכmtεm rεdכks di wet gεn fכ fat mays dεm, we bin riliyt to di inkrεs fεt כksidεshכn na di bכdi εn di inkrεs plasma glycerol lεvεl (wan indikεtכ fכ lipolysis). difrεnt lεk hGH, AOD 9604 nכ de mek di hεpa glycemia כ ridyus insulin sekreshכn. AOD 9604 nכ de kכmpit wit di hGH rεsεpכta εn i nכ de indyuz sεl proliferashכn lεk hGH. dis de kכnfכm di kכnsεpt fכ hGH as prohכmon, we de sho se di fragmεnt fכ hGH kin akt insay wan we difrεnt frכm di tradishכnal hGH stimulashכn path ^[4]. .

Wetin na di ifɛkt we AOD 9604 gɛt pan di liva?

di ifekt we AOD 9604 gεt pan di liva de mεnli rεflek in rεgεdyushכn ifekt pan fεt mεtabolism. as sεntetik polipεptida we de miks di lipolytic fכnshכnal domεn fכ di hכmon gכt hכmon (hGH), AOD 9604 kin promuot lipolysis, inhεbit lipojenεsis, εn shift di bכdi in enεji mεtabolism frכm glukכs mεtabolism to fεt mεtabolism. dis mεkanism fכ akshכn de εp fכ ridyus di fεt we de kכmכt na di liva, so dat de gi sכm digri fכ protεkshכn to di liva. fכ mεtabolik sik dεm lεk fεt liva, di weit lכs εn mεtabolik rεguleshכn ifekt dεm fכ AOD 9604 kin εp fכ impruv di fεt mεtabolism stetכs fכ di liva, rεdכks di bכdi pan di liva, εn dis kin mek di liva wok fayn. Bɔt naw, na smɔl dairekt stɔdi dɛn de bɔt di ifɛkt we AOD 9604 gɛt pan di liva. di ifekt dεm we de oba dεn mεnli spεkul bays pan in ifekt pan fεt mεtabolism, εn mכr sayntis risεch stil nid fכ vεrifik di spεsifi k liva protεkshכn ifekt dεm εn mεkanism dεm fכ akshכn.

Wetin na di minin fɔ AOD 9604?

AOD 9604 na sεntetik polipεptida we de miks di lipolytic fכnshכnal domεn fכ di hכmon gכt hכmon (HGH), εn in mεdikal aplikεshכn valyu na signifyant. insay di tritmεnt fכ fat εn mεtabolik sik dεm, AOD 9604 kin εfεktiv fכ protεkt lipolysis, inhibit lipogenesis, εn rεgul di bכdi in mεtabolik prכsεs, εp fכ fat pasεnshכn fכ lכs wet, impruv bכdi kכmכshכn, εn i gεt pכtεnshal aplikεshכn valyu fכ trit mεtabolik sik dεm lεk fεt liva. We yu kɔmpia am wit di kɔmplit ɔmon we de mek pɔsin gro, i de pul di sayd ɛfɛkt dɛn we kin mek pɔsin nɔ gɛt insulin ɛn i kin mek di blɔd shuga bɔku, so i kin sef we dɛn de du di tritmɛnt ɛn i fayn fɔ bɔku pipul dɛn we sik.

AOD 9604 gɛt impɔtant minin pan di fild fɔ drɔg risach ɛn divɛlɔpmɛnt. As drɔg fɔ lɔs wet wit wan spɛshal we fɔ akshɔn, i de gi nyu chuk fɔ trit fɔ fat, i de sho di pɔtnɛshɛl fɔ polypeptide drɔgs fɔ trit mɛtabolik sik dɛn, ɛn gi nyu aydia ɛn risach dairekshɔn fɔ di divɛlɔpmɛnt we go kam afta dat fɔ mɔ sef ɛn ifektiv weit lɔs drɔgs. apat frכm dat, di sεntesis εn risεch fכ AOD 9604 dεn dכn prכmot di divεlכpmεnt fכ di fil fכ polipεptida drog dεm, vεrifik di fεsibiliti fכ polipεptida dכg dεm fכ miks εn rεgul spεsifi k fysiolojikal fכnshכn dεm na di bכdi, εn gi valyu εkspiriεns fכ disayn, sεntesis, εn optimizεshכn fכ polipεptida dכg dεm.

Fɔ mek pipul dɛn gɛt wɛlbɔdi layf, dɛn kin yuz AOD 9604 as ɔgzilari we fɔ ɛp pipul dɛn fɔ kɔntrol dɛn wet ɛn fɔ mek dɛn kɔntinyu fɔ gɛt wɛlbɔdi. Fat na siriɔs prɔblɛm na di sosayti tide, ɛn di ifɛkt we i gɛt fɔ lɔs dɛn wet kin gi ɔda sɔpɔt to pipul dɛn we gɛt prɔblɛm fɔ lɔs dɛn wet tru simpul it ɛn ɛksesaiz. pan di sem tεm, bay we i de rεgεl di fεt mεtabolism, i de εp fכ impruv di bכdi in mεtabolik hεlth stetכs, rεdכks di bכdi lipid lεvεl, rεdכks di fεt we de dכn na di bכdi vεsul dεm, rεdכks di risk fכ mεtabolik-rεlatεd sik dεm lεk kכdivaskyul sik dεm, εn impruv di kwaliti fכ layf.

AOD 9604 de ple impɔtant pat bak fɔ protɛkt di bɛsis risach. in risεch de εp fכ dip fכ εksplכr di mεkanism fכ akshכn fכ di hכmon gכt hכmon, spεshal wan in spεsifi k rol εn signal path fכ di rεguleshכn fכ fεt mεtabolism. tru di risach pan AOD 9604, sayɛnsman dεm kin כndastand bεtεh aw di gכt כmon de εksyεrt in fysiolojikal fכnshכn dεm tru di intarakshכn bitwin spεsifi k dכmεn dεm εn rεsεpכta dεm, εn aw dεn fכnshכn dεm ya de chenj כnda difrεn fysiolojikal εn patכlayz kכndishכn dεm. apat frכm dat, dεn kin yuz AOD 9604 as risεch tul fכ risεch we rilet to fεt mεtabolism, fכ εp sayɛnsman dεm stכdi di prכsεs dεm fכ fεt dεkכmpכzishכn, jεnereshכn, εn sεl signal transdyushכn, fכ sho di mכlikul mεkanism dεm εn rεgεdyushכn nεtwכk dεm fכ fεt mεtabolism, εn gi wan tiori bεsis fכ divεlכpmεnt fכ tritmεnt mεtכd dεm εn dכg fכ abnכmal fεt mεtabolism.

Di pɔsin we rayt di buk na di Jɔnal

Heffernan, MA gɛt fɔ du wit di Yunivasiti ɔf Limɛrik ɛn i de wok tranga wan pan sɔm akademik disiplin dɛn. dis dεm inklud Endocrinology & Metabolism, usay risεch kin fכkus pan di כmon fכnshכn dεm εn mεtabolik prכsεs dεm insay di bכdi. Insay Polima Sayns, dɛn wok kin involv fɔ stɔdi bɔt polima matirial dɛn, aw dɛn kin mek dɛn, aw dɛn kin yuz dɛn, ɛn aw dɛn kin yuz dɛn. Fisioloji go kɔba di wok ɛn prɔses dɛm fɔ liv ɔrganizm dɛm, we Nutrition & Dietetics gɛt fɔ du wit di sayɛns bɔt it, nyutrishɔn, ɛn it prɔsis.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

di risach we Heffernan du kin εksplכr di intasekshכn dεm fכ dεn fil dεm ya, lεk fכ divεlכp polimכr-bεys drog dεlivεri sistεm fכ mεtabolik dizכrd כ stכdi di fysiolojikal impak dεm we nyutrishכnal intavεnshכn dεm de yuz advans mεtirial sayns tεknik dεm. Dɛn wok de ɛp fɔ ɔndastand mɔ bɔt bayolojikal prɔses ɛn fɔ divɛlɔp nyu sɔlvishɔn dɛn na wɛlbɔdi biznɛs ɛn matirial sayɛns. Heffernan, MA de list in di rεfrεns כf saytεshכn [4].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Heffernan M, Summers RJ, Thorburn A, ɛn ɔda pipul dɛn. di ifekt dεm we hכman GH εn in lipolytic fragmεnt (AOD9604) gεt pan lipid mεtabolism we de fכlכ krכnik tritmεnt in obes mays εn β3-AR knock-out mays[J]. Ɛndokrinɔlɔji, 2001,142(12):5182-5189.DOI:10.1210/ɛn.142.12.5182.

[2] Kwon DR, Park G Y. Efεkt כf Intra-artikulכr Injεkshכn כf AOD9604 wit כ witout Hyaluronic Acid in Rabit Osteoarthritis Model[J]. Annals of Klinik ɛn Labɔrɔtɔri Sayns, 2015,45(4):426-432. http://www.annclinlabsci.org/content/45/4/426.lɔng, di wan dɛn we de stɔdi bɔt di Baybul

[3] Kɔks H. D., Smeal S. J., Hughes C. M., ɛn ɔda pipul dɛn. Ditekshɔn ɛn in vitro mɛtabolism fɔ AOD9604[J]. Drug Tɛstin ɛn Analysis, 2015,7(1):31-38.DOI:10.1002/dta.1715.

[4] Heffernan M. A., Thorburn A. W., Fam B., ɛn ɔda pipul dɛn. inkrεs pan fεt כksidεshכn εn weit lכs insay fat mays dεm we kכz fכ krכnik tritmεnt wit hכman gכt hכmon כ wan modifyed C-tεrminal fragmεnt[J]. Int ɛ rnash ɔ nal J ɔ rnal ɔ f Obesiti, 2001,25(10):1442-1449.DOI:10.1038/sj.ijo.0801740.

[5] Ng F. M., Sun J., Sharma L., ɛn ɔda pipul dɛn. Mεtabolik stכdi dεm fכ wan Sεntetik Lipolytic Domain (AOD9604) fכ Human Grכwth Hכmon[J]. Hɔmɔn Risach in Pidiatrik, 2001,53:274-278. DOI: 10.1159/000053183, ɛn di ɔda wan dɛn

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.